Bristol Myers breaks the bank on Eisai's folate receptor ADC drug, laying out more than $3B+ for rights
For years, innovation in oncology has been a crapshoot with Big Pharma — the whales at the table — dropping the big bucks for the key to the next generation of tumor fighters. Bristol Myers Squibb hasn’t exactly made a name for being an innovator in the space, but that doesn’t mean it won’t splash in when it sees a potential winner.
Now, with a massive check in hand, the drugmaker is willing to put its intuition to the test.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 164,000+ biopharma pros reading Endpoints daily — and it's free.